Shamat Fathi Shamat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shamat Fathi Shamat has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Ayesha Azhar
Department of Internal Medicine, Dow University of Health Sciences
2 shared publications - Muskan Asim Taimuri
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan
2 shared publications - Areeba Ikram
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication - Mohamed Ashraf Osman
Faculty of Medicine, National Ribat University, Khartoum, Sudan
1 shared publication - Muhammad Meeran Saleem
Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication - Rabia Owais
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication
Latest Publications
- Open Access
- 18 December 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (2) , 923-925
Novel FDA-approved zavegepant drug for treating migraine
Migraine is a complex neurological disorder characterized by recurring episodes of severe headaches. The pathophysiology of migraine involves abnormalities in neuronal networks, cortical spreading depression, and sensitization of trigeminovascular pathways. The global prevalence of migraine has increased substantially, warranting advancements in treatment strategies. A significant trigger in migraine pathophysiology is calcitonin gene-related peptide (CGRP). Several drugs, such as gepants and monoclonal antibodies (MABs) targeting CGRP or its receptor, have been developed to antagonize CGRP signaling. Zavegepant (Zavzpret), a novel CGRP receptor antagonist, has recently been approved by the FDA for the acute treatment of migraine. Clinical trials have demonstrated its efficacy in providing headache and symptom relief, with a statistically significant percentage of patients achieving freedom from headaches and most bothersome symptoms. Despite mild adverse effects, such as taste disorders and nausea, Zavzpret’s overall safety profile remains acceptable.
- 18 December 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (2) , 923-925
Open AccessNovel FDA-approved zavegepant drug for treating migraine
Migraine is a complex neurological disorder characterized by recurring episodes of severe headaches. The pathophysiology of migraine involves abnormalities in neuronal networks, cortical spreading depression, and sensitization of trigeminovascular pathways. The global prevalence of migraine has increased substantially, warranting advancements in treatment strategies. A significant trigger in migraine pathophysiology is calcitonin gene-related peptide (CGRP). Several drugs, such as gepants and monoclonal antibodies (MABs) targeting CGRP or its receptor, have been developed to antagonize CGRP signaling. Zavegepant (Zavzpret), a novel CGRP receptor antagonist, has recently been approved by the FDA for the acute treatment of migraine. Clinical trials have demonstrated its efficacy in providing headache and symptom relief, with a statistically significant percentage of patients achieving freedom from headaches and most bothersome symptoms. Despite mild adverse effects, such as taste disorders and nausea, Zavzpret’s overall safety profile remains acceptable.
- 4 September 2023
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 193 (2) , 831-832
Potential of near-infrared spectroscopy (NIRS) as a non-invasive diagnostic tool to contain a global outbreak of malaria
- 4 September 2023
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 193 (2) , 831-832
Potential of near-infrared spectroscopy (NIRS) as a non-invasive diagnostic tool to contain a global outbreak of malaria
- Open Access
- 16 August 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (10) , 4909-4912
Briumvi: a breakthrough in the treatment of relapsing multiple sclerosis: a review
Multiple sclerosis (MS) is a chronic systemic autoimmune disorder characterized by plaques of demyelination, autoimmune inflammation, and astrocytic gliosis. The primary cells involved in the pathophysiology of MS are T cells. However, B cells have recently been implicated in the pathophysiology of the disease. Therefore, researchers have been exploring B cell therapy as an alternative treatment option for MS. B cell therapy is based on the targeted depletion of CD20-positive B cells. Rituximab, ocrelizumab, and ofatumumab are anti-CD20 antibodies already approved. Briumvi, the fourth type of anti-CD20 antibody was approved by FDA in December 2022, for the treatment of relapsing types of MS, including relapsing-remitting multiple sclerosis, active secondary progressive multiple sclerosis, and clinically isolated syndromes after the drug was tested in two randomized, double-blind, phase III, ULTIMATE I, and II trials which compared Briumvi (ublituximab) with Aubiago (teriflunomide). Ublituximab was found to have a much lower annual relapse rate in the ULTIMATE II trials than teriflunomide. Briumvi is a chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. Its mechanism of action involves several distinct processes that collectively lead to the depletion of B cells and suppression of the immune response. The primary mode of action of Briumvi is its high-affinity binding to CD20. Infusion-related reactions are the most common side effects encountered following intravenous administration of ublituximab.
- 16 August 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (10) , 4909-4912
Open AccessBriumvi: a breakthrough in the treatment of relapsing multiple sclerosis: a review
Multiple sclerosis (MS) is a chronic systemic autoimmune disorder characterized by plaques of demyelination, autoimmune inflammation, and astrocytic gliosis. The primary cells involved in the pathophysiology of MS are T cells. However, B cells have recently been implicated in the pathophysiology of the disease. Therefore, researchers have been exploring B cell therapy as an alternative treatment option for MS. B cell therapy is based on the targeted depletion of CD20-positive B cells. Rituximab, ocrelizumab, and ofatumumab are anti-CD20 antibodies already approved. Briumvi, the fourth type of anti-CD20 antibody was approved by FDA in December 2022, for the treatment of relapsing types of MS, including relapsing-remitting multiple sclerosis, active secondary progressive multiple sclerosis, and clinically isolated syndromes after the drug was tested in two randomized, double-blind, phase III, ULTIMATE I, and II trials which compared Briumvi (ublituximab) with Aubiago (teriflunomide). Ublituximab was found to have a much lower annual relapse rate in the ULTIMATE II trials than teriflunomide. Briumvi is a chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. Its mechanism of action involves several distinct processes that collectively lead to the depletion of B cells and suppression of the immune response. The primary mode of action of Briumvi is its high-affinity binding to CD20. Infusion-related reactions are the most common side effects encountered following intravenous administration of ublituximab.